49,886 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Bought by EntryPoint Capital LLC

EntryPoint Capital LLC bought a new position in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 49,886 shares of the company's stock, valued at approximately $684,000. EntryPoint Capital LLC owned 0.05% of Myriad Genetics at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Segall Bryant & Hamill LLC boosted its position in shares of Myriad Genetics by 137.4% during the fourth quarter. Segall Bryant & Hamill LLC now owns 72,117 shares of the company's stock worth $989,000 after buying an additional 41,739 shares during the period. Vanguard Group Inc. boosted its position in Myriad Genetics by 2.7% during the 4th quarter. Vanguard Group Inc. now owns 10,591,043 shares of the company's stock worth $145,203,000 after acquiring an additional 279,379 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Myriad Genetics during the 4th quarter worth approximately $247,000. Hillsdale Investment Management Inc. raised its holdings in shares of Myriad Genetics by 8.6% in the fourth quarter. Hillsdale Investment Management Inc. now owns 166,300 shares of the company's stock valued at $2,280,000 after purchasing an additional 13,120 shares during the last quarter. Finally, Sei Investments Co. lifted its position in shares of Myriad Genetics by 7.4% in the fourth quarter. Sei Investments Co. now owns 2,526,761 shares of the company's stock worth $34,642,000 after purchasing an additional 174,770 shares in the last quarter. Institutional investors own 99.02% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on MYGN. Raymond James reiterated an "outperform" rating and issued a $19.00 price target (down from $27.00) on shares of Myriad Genetics in a research note on Tuesday, February 25th. Piper Sandler raised shares of Myriad Genetics from a "neutral" rating to an "overweight" rating and raised their target price for the company from $11.50 to $12.50 in a research note on Wednesday, March 12th. Leerink Partnrs downgraded Myriad Genetics from a "strong-buy" rating to a "hold" rating in a research note on Monday, December 9th. Craig Hallum started coverage on Myriad Genetics in a report on Wednesday, February 12th. They set a "buy" rating and a $29.00 price target for the company. Finally, Leerink Partners downgraded shares of Myriad Genetics from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $30.00 to $21.00 in a report on Monday, December 9th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $21.89.

Myriad Genetics Price Performance

Shares of MYGN stock traded down $0.34 on Friday, hitting $8.88. 599,366 shares of the company's stock were exchanged, compared to its average volume of 877,958. The stock has a market cap of $810.82 million, a P/E ratio of -6.83 and a beta of 1.79. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. The company has a 50 day moving average of $11.76 and a 200 day moving average of $16.50. Myriad Genetics, Inc. has a 12 month low of $8.70 and a 12 month high of $29.30.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.12). The firm had revenue of $210.60 million during the quarter, compared to the consensus estimate of $210.35 million. Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. During the same quarter in the previous year, the company posted ($0.12) earnings per share. On average, equities research analysts predict that Myriad Genetics, Inc. will post -0.3 EPS for the current year.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.